Objective: Excessive mitochondrial fission has been associated with several neurodegenerative diseases, including Huntington’s disease (HD). Consequently, mitochondrial dynamics has been suggested to be a promising therapeutic target for Huntington’s disease. Mitochondrial fission depends on recruitment of Drp1 to mitochondria, and Mff (mitochondrial fission factor) is one of the key adaptor proteins for this process. Removal of Mff therefore greatly reduces mitochondrial fission. Here we investigate whether removal of Mff can mitigate HD-associated pathologies in HD transgenic mice (R6/2) expressing mutant Htt.
Method: We compared the phenotype of HD mice with and without Mff. The mice were monitored for lifespan, neurological phenotypes, Htt aggregate formation, and brain histology.
Results: We found that HD mice lacking Mff display more severe neurological phenotypes and have shortened lifespans. Loss of Mff does not affect mutant Htt aggregation, but it accelerates HD pathology, including neuronal loss and neuroinflammation.
Conclusions: Our data indicate a protective role for mitochondrial fission in HD and suggest that more studies are needed before manipulation of mitochondrial dynamics can be applied to HD therapy.
Huntington’s disease (HD) is an autosomal dominant, neurodegenerative disease characterized by progressive, abnormal involuntary movements (chorea), rigidity, cognitive decline, and psychiatric symptoms1. There is marked loss of neurons in the caudate nucleus, putamen, and cerebral cortex2,3. The disease is caused by a CAG triplet expansion in exon 1 of the HTT (huntingtin) gene4. This mutation results in an enlarged stretch of polyglutamines in the N-terminus of Htt, with the length correlating with severity of disease. Disease alleles containing 40 or more CAG repeats are fully penetrant1,5. There is evidence that Htt with an expanded polyglutamine region impairs neuronal function via a toxic gain-of-function effect, in part because polyglutamine repeats are prone to aggregation. Mutant Htt has been shown to interact with multiple proteins and to interfere with both cytoplasmic and nuclear functions6. Mutant Htt associates with mitochondria7, and this organelle is among the potential cellular targets of mutant Htt. HD mutant cells have been shown to have defective mitochondrial function, including ATP production8, calcium handling8,9, transport7,10,11 and dynamics10,11,12,13.
Mitochondria are dynamic organelles whose functions are dependent on appropriate balancing of fusion versus fission14,15. Mitochondrial fission is mediated by Drp1 (dynamin related protein 1), a large GTP hydrolyzing enzyme of the dynamin superfamily. During mitochondrial fission, Drp1 is recruited from the cytosol onto the mitochondrial surface by one of several outer membrane proteins that serve as Drp1 receptors. There are currently four putative Drp1 receptors–Fis1, Mff, MiD49, and MiD5114. Although Fis1 clearly functions to recruit the Drp1 ortholog, Dnm1p, in yeast, its role in mammalian cells is currently unclear. Cells lacking Fis1 show little or no defect in mitochondrial fission16,17. Mff has a prominent role in recruiting Drp1, and cells lacking Mff show elongated mitochondrial tubules and have substantially less Drp1 on mitochondria16,17. MiD49 and MiD51 also recruit Drp1, but the recruited Drp1 appears to be kept, at least initially, in an inactive state17,18.
Expression of mutant Htt appears to result in aberrantly increased mitochondrial fission. HD patient cells, as well as cells engineered to express mutant Htt, show mitochondrial fragmentation due to activation of Drp110,11. Mutant Htt physically interacts with Drp1 and elevates its GTP hydrolysis activity10,11. Two studies suggest that inhibiting mitochondrial fission has therapeutic effects in HD cell and animal models. First, in cultured striatal neurons expressing mutant Htt, treatment with the Drp1 inhibitor Mdivi1 (mitochondrial division inhibitor 1) improved mitochondrial morphology, reduced reactive oxygen species (ROS), and improved cell viability19. A recent report, however, questions the specificity of Mdivi1 by showing that it has effects on mitochondrial respiration and ROS production unrelated to its activity against Drp120. Second, treatment of cell and mouse models of HD with P110, a peptide inhibitor of Drp1, restored normal mitochondrial morphology, improved mouse behavioral deficits, and prolonged lifespan21. P110 was designed to block the interaction of Drp1 with Fis122. As noted above, Fis1 is a mitochondrial outer membrane protein postulated to recruit Drp1 from the cytosol onto the mitochondrial surface. These findings have raised the intriguing possibility that mitochondrial fission is an attractive therapeutic target for HD patients.
Given these results showing the functional importance of Drp1 in HD pathogenesis, we tested whether removal of Mff could ameliorate the neurological phenotypes found in the HDR6/2 mouse model. Surprisingly, we find that removal of Mff worsened the neurological phenotypes of HDR6/2mice. Although loss of Mff did not increase the number of Htt-positive aggregates, it was associated with increased neuronal loss, astrogliosis, and neuroinflammation.
Female mice with ovaries transplanted from HDR6/2 mice were obtained from The Jackson Laboratory (Bar Harbor). Mffgt/gt mice lack all Mff isoforms, and their generation has been described15 . Ovarian transplanted (OT) HDR6/2 females were crossed with Mffgt/gt males to generate Mff+/-, HDR6/2 males. Mffgt/+ females were crossed with Mffgt/+, HDR6/2 males to generate the following littermate cohorts: Mff+/+;Mff+/+, HDR6/2;Mffgt/gt; Mffgt/gt, HDR6/2. Both the Mffgt/gt and HDR6/2 lines are on mixed genetic backgrounds. The CAG repeat numbers in the relevant cohorts were determined by genomic DNA analysis by Laragen (Culver City, CA). The average CAG repeat number did not vary significantly between the HDR6/2 and Mff
Four cohorts of 15 animals were used. This study was approved by the Caltech Institutional Animal Care and Use Committee, and mouse maintenance and experiments were conducted in accordance with approved protocols. Humane endpoints were established and included >15% weight loss, >10% dehydration, pain, distress, or inability to ambulate. None of the experimental animals met these criteria. Cohorts were sacrificed by CO2 inhalation at 12 weeks for histological and biochemical analysis.
Behavioral analysis and sample preparation
Body weight measurement and clasping assessment were evaluated weekly from 6-11 weeks of age. The clasping assessment test was performed by suspending mice by the tail for 30 s and then recording hindlimb clasping behavior. Grip strength measurement and the open field test were evaluated at 10 weeks of age. For the grip strength test, mice were placed towards the pull bar (Chatillon grip strength meter, Columbus instruments), and forelimb grip forces were measured until they released their grip from the bar. For the Open Field test, mice were allowed to move around the chamber freely. Total travelled distance was recorded with a digital camera using EthoVision software (Noldus).For biochemical analysis, mice were anesthetized with isoflurane, sacrificed, and transcardially perfused with ice-cold PBS. The striatum was microdissected from the right hemispheres and stored at -80°C until Western blot analysis. Left hemispheres were post-fixed with formalin (Sigma-Aldrich) and processed for immunohistochemistry.
Serial 30 μM coronal brain tissue sections were cut with a cryowmicrotome (Microm HM550, Thermo Scientific). For visualization of target molecules, brain tissue sections were immunostained with the following primary antibodies: EM48 (1:1000; Millipore), anti-NeuN (1:1000; Millipore), anti-glial fibrillary acidic protein (GFAP; 1:1000, Sigma-Aldrich), anti-ionized calcium binding adaptor molecule-1 (Iba-1; 1:500, Wako). Fluorescent conjugated secondary antibodies were obtained from Thermo Fisher: goat-anti-mouse Alexa 488 (1:500) and goat-anti-rabbit Alexa 568 (1:500). All stained sections were mounted on micro slides (VWR) with Fluro-Gel (EMS). For Nissl staining, tissue sections were washed with PBS and mounted on micro slides (VWR). Slides were dried at room temperature for overnight and stained with cresyl violet (Sigma-Aldrich) for 3 min. Stained sections were cover-slipped in micro slides (VWR) with xylene-based mounting medium.
Mouse brains were lysed in 1% Triton X-100 buffer (10 mM Tris, pH 7.4, 1% Triton X-100, 150 mM NaCl, 10% glycerol, and 0.2 mM PMSF) containing protease inhibitors (Sigma-Aldrich). After centrifugation at 15,000 x gfor 20 min at 4 °C, the supernatant was collected as the Triton-soluble fraction. The Triton-insoluble pellet was resuspended in lysis buffer containing 10 mM Tris (pH 7.4), 4% SDS buffer. Protein concentrations were determined with the DCTMprotein assay kit (Bio-Rad). Protein samples were separated on NuPAGE 3–8% Tris-Acetate gels (Thermo Fisher) and transferred to a PVDF membrane. Membranes were incubated with the following primary antibodies: EM48 (1:1000; Millipore), anti-beta-actin (1:10000, Sigma-Aldrich). Immunoreactivity was visualized by a chemiluminescent HRP substrate (Millipore).
Quantification of Immunoreactivity
For quantification of immunoreactivity, tissue sections were obtained from the striatum. Five random acquisition areas in the striatum were considered for each tissue section. NeuN-positive or Nissl-positive neurons were counted using ImageJ software (National Institutes of Health). To quantify the GFAP or Iba-1-positive areas, the immunofluorescence region in the striatum was analyzed using the ImageJ software (National Institutes of Health).
Statistical significance of data was analyzed with ANOVA test by Prism 6 software (GraphPad). Results are presented as means ± standard error of the mean. Survival of different cohorts were analyzed by Kaplan-Meier survival and log-rank analysis.
Removal of Mff exacerbates behavioral phenotypes in the mouse HDR6/2 model
In addition to weight loss, the mouse HDR6/2 model has been documented to have several features of neurological disease, including limb clasping behavior, reduced forelimb grip strength, and diminished spontaneous motor activity. To address the effect of Mff on HD pathology, we designed a mating scheme to generate HDR6/2 mice lacking Mff. In a previous study15, we engineered a mouse line (Mffgt/gt) containing a gene trap insertion within the Mff locus that constitutively eliminates expression of all Mff protein isoforms, results in secondary reduction of Drp1 levels, and causes a severe mitochondrial fission defect. We first crossed Mffgt/gt mice with ovarian transplanted females that were hemizygous for HDR6/2 to generate Mffgt/+, HDR6/2 males. These males were crossed with Mffgt/+ females to generate experimental (Mffgt/gt, HDR6/2) and control (Mff+/+; HDR6/2; Mffgt/gt) animals (Fig 1A).
To determine whether removal of Mff altered the life span in HDR6/2 mice, we evaluated longevity and found that Mffgt/gt, HDR6/2 mice began dying several weeks earlier than HDR6/2 mice and lived to only ~12 weeks (Fig 1B). In contrast to wildtype mice, HDR6/2 mice show moderate weight loss between weeks 6-11 (Fig. 2A). The weights of Mffgt/gt mice also lag behind wildtype mice, consistent with our previous results15. Interestingly, Mffgt/gt, HDR6/2 mice showed a more severe weight loss than either of these mutant mice (Fig 2A; p=0.002). Furthermore, Mffgt/gt, HDR6/2 mice exhibited markedly higher clasping behavior from 8 to 11 weeks, compared to HDR6/2 mice (Fig 2B). Mffgt/gt, HDR6/2 mice were significantly weaker than either Mffgt/gt or HDR6/2mice in forelimb grip force (Fig 2C). Mffgt/gt, HDR6/2 mice also showed less spontaneous activity than HDR6/2 mice when allowed to explore an open field chamber, although the result did not reach statistical significance (Fig 2D). Taken together, these findings demonstrate that the Mff knockout exacerbates the behavioral and neurological phenotypes of HDR6/2 mice.
Modulation of Mff does not alter mutant Htt aggregation in HDR6/2 mice
To examine the impact of Mff modulation on mutant huntingtin aggregation, we isolated the striatum of each mice and performed immunoblot analysis. In HDR6/2 mice, the detergent-insoluble fraction of the striatum showed high accumulation of mutant Htt aggregates. The levels were unchanged in Mffgt/gt, HDR6/2 mice (Fig 3A). Using the EM48 antibody to visualize Htt aggregates in striatal sections, we found that the number of Htt inclusions in HDR6/2 mice was unchanged by removal of Mff (Fig 3B). Thus, even though loss of Mff increases the severity of the neurological phenotype in the HDR6/2 model, immunohistochemical and biochemical assays indicate that it does not affect deposition of mutant Htt aggregates.
Loss of Mff increases neuronal loss and inflammation in HDR6/2 mice
Previous studies showed that HD mice exhibited extensive neuronal loss in the striatum area23,24. To test whether Mff influences progressive neuronal loss, we performed immunohistochemistry of brain sections among each group with an antibody against NeuN, a neuronal marker protein. Quantitative analysis revealed that HDR6/2 mice showed a decreased number of NeuN-positive neurons relative to wildtype mice, in agreement with previous studies [23, 24] (Fig 4A). Furthermore, Mffgt/gt, HDR6/2 mice contained markedly fewer (~25%) NeuN-positive neurons compared to HDR6/2 mice. Subsequent examinations with Nissl staining showed similar results (Fig 4B).
Accumulation of mutant Htt has been suggested to cause neuroinflammation that potentially promotes neurotoxicity in HD25,26,27. Neuroinflammation manifests as elevated astrocyte and microglia activation28. To measure the neuroinflammatory response, we performed immunostaining with GFAP (glial fibrillary acidic protein), an astrocyte marker (Fig 5A), and Iba-1 (ionized calcium binding adaptor molecule-1), a microglia marker (Fig 5B). Interestingly, we found significantly elevated GFAP and Iba-1 immunoreactivity in Mffgt/gt, HDR6/2mice compared to HDR6/2 mice. These results suggest that Mff depletion promotes loss of neurons and an elevated neuroinflammatory response in HDR6/2 mice.
HD cells have been shown to have aberrantly increased mitochondrial fragmentation, an effect attributed to increased activation of Drp1 and fission10,11. Given that peptide-based inhibition of Drp1 has been reported to ameliorate the neurological symptoms and mortality of HDR6/2 mice21, we wondered whether a similar effect would be found with removal of Mff. Mff is a major receptor for Drp1, and embryonic fibroblasts from our Mffgt/gtmice have substantially reduced recruitment of Drp1 and fission activity16,17. Its role in mitochondrial fission has been shown in a variety of cultured cells from Drosophila, human, and mouse, and it is expressed in the mammalian brain30. However, we found no evidence that removal of Mff could improve the phenotype of HDR6/2 mice. We found instead that loss of Mff resulted in more severe neurological symptoms and earlier lethality. Loss of Mff did not increase the levels of aggregated Htt, but did increase loss of neurons, astrogliosis, and neuroinflammation.
P110 was designed to block a putative interaction between Drp1 and Fis122. The function of Fis1 in Drp1 recruitment to mitochondria remains unclear, due to the observation that cells lacking Fis1 show little or no defect in Drp1 recruitment or mitochondrial fission16,17. It remains possible that Fis1 does play a role in mitochondrial fission in specialized cell types or under particular cellular stress conditions. P110 has also been shown bind recombinant Drp1 directly and inhibit its GTP hydrolysis activity22. More work will be required to understand the mechanism through which P110 affects the phenotype of HDR6/2 mice.
Our results indicate that loss of Mff aggravates the neurological symptoms of HDR6/2mice. Therefore, although there is evidence that inhibition of Drp1 function can improve the phenotype of HDR6/2 mice21, Mff seems to not be the relevant Drp1 receptor for this effect. The P110 results suggest a role for Fis1. MiD49 and MiD51 also remain possibilities. It is currently unclear why there are potentially four Drp1 receptors, with each playing a role in mitochondrial fission17,31,32. This diversity of Drp1 receptors may allow regulation of Drp1 function to be tailored to the cellular state. For example, Mff, MiD49, and MiD51 have different effects on Drp1 function upon recruitment. Unlike Mff, MiD49 and MiD51 have inhibitory effects on Drp1 function17,31 , and MiD51 has been shown to inhibit the GTP hydrolysis activity of Drp1 . Additional stimuli are presumably necessary to activate Drp1 once it has been recruited by MiD49 or MiD51. MiD49 and MiD51 also appear to play stronger roles in mediating mitochondrial fission during apoptosis compared to Mff32.
Our results further suggest that Mff is protective in the context of Htt containing an expanded polyglutamine repeat. With Mff is removed, there is increased neuronal cell loss, increased astrogliosis, and increased expression of neuroinflammatory markers. These detrimental effects may arise because loss of Mff upsets the delicate balance between mitochondrial fusion and fission, and as a result neurons are less able to cope with Htt aggregates. Our previous mouse studies suggest that an appropriate balance between these opposing processes is critical for mitochondrial health. Multiple setpoints for fusion versus fission are compatible with mitochondrial function, but the levels have to been carefully balanced15. Mffgt/gt mice show reduced respiratory chain function, as shown in cardiomyocytes, and this dysfunction is associated with reduced mitochondrial density and aberrant mitophagy17. If these cellular defects extend to neurons, they may help to explain the worsening of the HDR6/2 phenotype.
Although inhibition of mitochondrial fission has been proposed as a therapeutic approach for HD, we find that removal of Mff, a mitochondrial fission factor, exacerbates the neurological phenotypes of HDR6/2 mice.Therefore, our results indicate that a deeper understanding of mitochondrial dynamics in HD is required before mitochondrial fission can be considered a therapeutic avenue for HD.
Data Availability Statement
The raw data for graphs in Figures 1-5 are available at https://figshare.com/s/584ca97ed838e5de3bde, with DOI: 10.6084/m9.figshare.6052007.
Competing Interests Statement
The authors have declared that no competing interests exist.
This work was funded by grant A-11059 from the CHDI Foundation (https://chdifoundation.org). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
- Walker FO. Huntington's disease. Lancet. 2007 Jan 20;369(9557):218-28. PubMed PMID:17240289.
- Estrada Sánchez AM, Mejía-Toiber J, Massieu L. Excitotoxic neuronal death and the pathogenesis of Huntington's disease. Arch Med Res. 2008 Apr;39(3):265-76. PubMed PMID:18279698.
- Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011 Jan;10(1):83-98. PubMed PMID:21163446.
- Saudou F, Humbert S. The Biology of Huntingtin. Neuron. 2016 Mar 2;89(5):910-26. PubMed PMID:26938440.
- Langbehn DR, Hayden MR, Paulsen JS. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):397-408. PubMed PMID:19548255.
- Harjes P, Wanker EE. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci. 2003 Aug;28(8):425-33. PubMed PMID:12932731.
- Orr AL, Li S, Wang CE, Li H, Wang J, Rong J, Xu X, Mastroberardino PG, Greenamyre JT, Li XJ. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci. 2008 Mar 12;28(11):2783-92. PubMed PMID:18337408.
- Seong IS, Ivanova E, Lee JM, Choo YS, Fossale E, Anderson M, Gusella JF, Laramie JM, Myers RH, Lesort M, MacDonald ME. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet. 2005 Oct 1;14(19):2871-80. PubMed PMID:16115812.
- Oliveira JM, Jekabsons MB, Chen S, Lin A, Rego AC, Gonçalves J, Ellerby LM, Nicholls DG. Mitochondrial dysfunction in Huntington's disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice. J Neurochem. 2007 Apr;101(1):241-9. PubMed PMID:17394466.
- Shirendeb UP, Calkins MJ, Manczak M, Anekonda V, Dufour B, McBride JL, Mao P, Reddy PH. Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease. Hum Mol Genet. 2012 Jan 15;21(2):406-20. PubMed PMID:21997870.
- Song W, Chen J, Petrilli A, Liot G, Klinglmayr E, Zhou Y, Poquiz P, Tjong J, Pouladi MA, Hayden MR, Masliah E, Ellisman M, Rouiller I, Schwarzenbacher R, Bossy B, Perkins G, Bossy-Wetzel E. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat Med. 2011 Mar;17(3):377-82. PubMed PMID:21336284.
- Reddy PH, Reddy TP, Manczak M, Calkins MJ, Shirendeb U, Mao P. Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases. Brain Res Rev. 2011 Jun 24;67(1-2):103-18. PubMed PMID:21145355.
- Shirendeb U, Reddy AP, Manczak M, Calkins MJ, Mao P, Tagle DA, Reddy PH. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum Mol Genet. 2011 Apr 1;20(7):1438-55. PubMed PMID:21257639.
- Chan DC. Fusion and fission: interlinked processes critical for mitochondrial health. Annu Rev Genet. 2012;46:265-87. PubMed PMID:22934639.
- Chen H, Ren S, Clish C, Jain M, Mootha V, McCaffery JM, Chan DC. Titration of mitochondrial fusion rescues Mff-deficient cardiomyopathy. J Cell Biol. 2015 Nov 23;211(4):795-805. PubMed PMID:26598616.
- Otera H, Wang C, Cleland MM, Setoguchi K, Yokota S, Youle RJ, Mihara K. Mff is an essential factor for mitochondrial recruitment of Drp1 during mitochondrial fission in mammalian cells. J Cell Biol. 2010 Dec 13;191(6):1141-58. PubMed PMID:21149567.
- Losón OC, Song Z, Chen H, Chan DC. Fis1, Mff, MiD49, and MiD51 mediate Drp1 recruitment in mitochondrial fission. Mol Biol Cell. 2013 Mar;24(5):659-67. PubMed PMID:23283981.
- Palmer CS, Elgass KD, Parton RG, Osellame LD, Stojanovski D, Ryan MT. Adaptor proteins MiD49 and MiD51 can act independently of Mff and Fis1 in Drp1 recruitment and are specific for mitochondrial fission. J Biol Chem. 2013 Sep 20;288(38):27584-93. PubMed PMID:23921378.
- Manczak M, Reddy PH. Mitochondrial division inhibitor 1 protects against mutant huntingtin-induced abnormal mitochondrial dynamics and neuronal damage in Huntington's disease. Hum Mol Genet. 2015 Dec 20;24(25):7308-25. PubMed PMID:26464486.
- Bordt EA, Clerc P, Roelofs BA, Saladino AJ, Tretter L, Adam-Vizi V, Cherok E, Khalil A, Yadava N, Ge SX, Francis TC, Kennedy NW, Picton LK, Kumar T, Uppuluri S, Miller AM, Itoh K, Karbowski M, Sesaki H, Hill RB, Polster BM. The Putative Drp1 Inhibitor mdivi-1 Is a Reversible Mitochondrial Complex I Inhibitor that Modulates Reactive Oxygen Species. Dev Cell. 2017 Mar 27;40(6):583-594.e6. PubMed PMID:28350990.
- Guo X, Disatnik MH, Monbureau M, Shamloo M, Mochly-Rosen D, Qi X. Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration. J Clin Invest. 2013 Dec;123(12):5371-88. PubMed PMID:24231356.
- Qi X, Qvit N, Su YC, Mochly-Rosen D. A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. J Cell Sci. 2013 Feb 1;126(Pt 3):789-802. PubMed PMID:23239023.
- Ellrichmann G, Blusch A, Fatoba O, Brunner J, Hayardeny L, Hayden M, Sehr D, Winklhofer KF, Saft C, Gold R. Laquinimod treatment in the R6/2 mouse model. Sci Rep. 2017 Jul 10;7(1):4947. PubMed PMID:28694434.
- Bissonnette S, Vaillancourt M, Hébert SS, Drolet G, Samadi P. Striatal pre-enkephalin overexpression improves Huntington's disease symptoms in the R6/2 mouse model of Huntington's disease. PLoS One. 2013;8(9):e75099. PubMed PMID:24040390.
- Aktas O, Ullrich O, Infante-Duarte C, Nitsch R, Zipp F. Neuronal damage in brain inflammation. Arch Neurol. 2007 Feb;64(2):185-9. PubMed PMID:17296833.
- Benraiss A, Wang S, Herrlinger S, Li X, Chandler-Militello D, Mauceri J, Burm HB, Toner M, Osipovitch M, Jim Xu Q, Ding F, Wang F, Kang N, Kang J, Curtin PC, Brunner D, Windrem MS, Munoz-Sanjuan I, Nedergaard M, Goldman SA. Human glia can both induce and rescue aspects of disease phenotype in Huntington disease. Nat Commun. 2016 Jun 7;7:11758. PubMed PMID:27273432.
- Ochaba J, Monteys AM, O'Rourke JG, Reidling JC, Steffan JS, Davidson BL, Thompson LM. PIAS1 Regulates Mutant Huntingtin Accumulation and Huntington's Disease-Associated Phenotypes In Vivo. Neuron. 2016 May 4;90(3):507-20. PubMed PMID:27146268.
- Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science. 2016 Aug 19;353(6301):777-83. PubMed PMID:27540165.
- Su YC, Qi X. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation. Hum Mol Genet. 2013 Nov 15;22(22):4545-61. PubMed PMID:23813973.
- Gandre-Babbe S, van der Bliek AM. The novel tail-anchored membrane protein Mff controls mitochondrial and peroxisomal fission in mammalian cells. Mol Biol Cell. 2008 Jun;19(6):2402-12. PubMed PMID:18353969.
- Osellame LD, Singh AP, Stroud DA, Palmer CS, Stojanovski D, Ramachandran R, Ryan MT. Cooperative and independent roles of the Drp1 adaptors Mff, MiD49 and MiD51 in mitochondrial fission. J Cell Sci. 2016 Jun 1;129(11):2170-81. PubMed PMID:27076521.
- Otera H, Miyata N, Kuge O, Mihara K. Drp1-dependent mitochondrial fission via MiD49/51 is essential for apoptotic cristae remodeling. J Cell Biol. 2016 Feb 29;212(5):531-44. PubMed PMID:26903540.